TY - JOUR T1 - Optimizing vaccine allocation for COVID-19 vaccines: critical role of single-dose vaccination JF - medRxiv DO - 10.1101/2020.12.31.20249099 SP - 2020.12.31.20249099 AU - Laura Matrajt AU - Julia Eaton AU - Tiffany Leung AU - Dobromir Dimitrov AU - Joshua T. Schiffer AU - David A. Swan AU - Holly Janes Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/16/2020.12.31.20249099.abstract N2 - Most COVID-19 vaccines require two doses, and current vaccine prioritization guidelines for COVID-19 vaccines assume full-dose vaccine deployment. However in the context of limited vaccine supply and an expanding pandemic, policymakers are considering single-dose vaccination as an alternative strategy. Using a mathematical model combined with optimization algorithms, we determined the optimal allocation with one and two doses of vaccine to minimize five metrics of disease burden under various degrees of viral transmission. Under low transmission, we show that the optimal allocation of vaccine critically depends on the level of single-dose efficacy (SDE). If the SDE is high, single-dose vaccination is optimal, preventing up to 36% more deaths than a strategy prioritizing full-dose vaccination for older adults first. With low or moderate SDE, mixed vaccination campaigns with coverage of all older adults with one dose are optimal. However, with modest or high transmission, vaccinating older adults first with two doses is best, preventing up to 41% more deaths than a single-dose vaccination given across all populations. Further, we show that maintaining social distancing interventions and speedy deployment are key for effective vaccination campaigns. Our work suggests that it is imperative to determine the efficacy and durability of single-dose vaccines, as mixed or single-dose vaccination campaigns may have the potential to contain the pandemic much more quickly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Fred Hutchinson Cancer Research Center discretionary funds awarded to Peter Gilbert.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data/code available upon request. ER -